Skip to content
Adam Torkildson – Lifestyle
Author:
XORTX Therapeutics Inc.
XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
November 13, 2026
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
October 8, 2026
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
September 18, 2026
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
September 10, 2026
XORTX Announces Director Resignation
July 31, 2026
XORTX Appoints New Director
July 29, 2026
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
June 12, 2026
XORTX Announces Closing of US$5 Million Public Offering
May 19, 2026